FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2085-2098 November 16, 2006 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Remuzzi, G. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined.

Methods In this open-label trial, we studied 1432 patients with chronic kidney disease, 715 of whom were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 13.5 g per deciliter and 717 of whom were assigned to receive a dose targeted to achieve a level of 11.3 g per deciliter. The median study duration was 16 months. The primary end point was a composite of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), and stroke.

Results A total of 222 composite events occurred: 125 events in the high-hemoglobin group, as compared with 97 events in the low-hemoglobin group (hazard ratio, 1.34; 95% confidence interval, 1.03 to 1.74; P=0.03). There were 65 deaths (29.3%), 101 hospitalizations for congestive heart failure (45.5%), 25 myocardial infarctions (11.3%), and 23 strokes (10.4%). Seven patients (3.2%) were hospitalized for congestive heart failure and myocardial infarction combined, and one patient (0.5%) died after having a stroke. Improvements in the quality of life were similar in the two groups. More patients in the high-hemoglobin group had at least one serious adverse event.

Conclusions The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 [ClinicalTrials.gov] .)

Source Information

From the Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston (A.K.S.); the Renal Division, Duke University Medical Center (L.S., D.R.), Duke Clinical Research Institute (L.S., S.S.), and the Department of Biostatistics and Bioinformatics, Duke University (H.B.) — all in Durham, NC; Ortho Biotech Clinical Affairs, Bridgewater, NJ (K.L.T., M.W.); and the Department of Medicine, University College Galway, Galway, Ireland (D.R.).

Address reprint requests to Dr. Singh at the Renal Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at asingh{at}partners.org.

Full Text of this Article

This article has been cited by other articles:

• Unger, E. F., Thompson, A. M., Blank, M. J., Temple, R. (2010). Erythropoiesis-Stimulating Agents -- Time for a Reevaluation. NEJM 362: 189-192 [Full Text]  
• Taylor, N. D., Way, J. C., Silver, P. A., Cironi, P. (2010). Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity. Protein Eng Des Sel 0: gzp085v1-gzp085 [Abstract] [Full Text]  
• Abboud, H., Henrich, W. L. (2010). Stage IV Chronic Kidney Disease. NEJM 362: 56-65 [Full Text]  
• Wetmore, J. B., Rigler, S. K., Mahnken, J. D., Mukhopadhyay, P., Shireman, T. I. (2010). Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?. Nephrol Dial Transplant 25: 198-205 [Abstract] [Full Text]  
• Singh, A. K. (2010). Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?. J. Am. Soc. Nephrol. 21: 2-6 [Full Text]  
• Sarraf, M., Masoumi, A., Schrier, R. W. (2009). Cardiorenal Syndrome in Acute Decompensated Heart Failure. CJASN 4: 2013-2026 [Abstract] [Full Text]  
• Eckardt, K.-U., Scherhag, A., Macdougall, I. C., Tsakiris, D., Clyne, N., Locatelli, F., Zaug, M. F., Burger, H. U., Drueke, T. B. (2009). Left Ventricular Geometry Predicts Cardiovascular Outcomes Associated with Anemia Correction in CKD. J. Am. Soc. Nephrol. 20: 2651-2660 [Abstract] [Full Text]  
• Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., Jahnig, P., Herrmann, M., Knauth, M., Bahr, M., Heide, W., Wagner, A., Schwab, S., Reichmann, H., Schwendemann, G., Dengler, R., Kastrup, A., Bartels, C., for the EPO Stroke Trial Group, (2009). Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. Stroke 40: e647-e656 [Abstract] [Full Text]  
• Marsden, P. A. (2009). Treatment of Anemia in Chronic Kidney Disease -- Strategies Based on Evidence. NEJM 361: 2089-2090 [Full Text]  
• Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., the TREAT Investigators, (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 361: 2019-2032 [Abstract] [Full Text]  
• Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A.-M., Froissart, M., Eckardt, K.-U. (2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. NEJM 361: 1848-1855 [Abstract] [Full Text]  
• Conway, B. N., Miller, R. G., Klein, R., Orchard, T. J. (2009). Prediction of Proliferative Diabetic Retinopathy With Hemoglobin Level. Arch Ophthalmol 127: 1494-1499 [Abstract] [Full Text]  
• Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., Sun, Y., Wasserman, S. M., van Veldhuisen, D. J. (2009). The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 11: 1071-1077 [Abstract] [Full Text]  
• Bacchus, S., O'Mara, N., Manley, H., Fishbane, S. (2009). Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists. The Annals of Pharmacotherapy 43: 1857-1866 [Abstract] [Full Text]  
• Treleaven, D. J, Clase, C. M (2009). Use of erythropoietins in patients with renal transplants. BMJ 339: b3825-b3825 [Full Text]  
• Heinze, G., Kainz, A., Horl, W. H, Oberbauer, R. (2009). Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 339: b4018-b4018 [Abstract] [Full Text]  
• Locatelli, F., Becker, H. (2009). Update on Anemia Management in Nephrology, Including Current Guidelines on the Use of Erythropoiesis-Stimulating Agents and Implications of the Introduction of "Biosimilars". The Oncologist 14: 16-21 [Abstract] [Full Text]  
• Besarab, A., Horl, W. H., Silverberg, D. (2009). Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome. The Oncologist 14: 22-33 [Abstract] [Full Text]  
• Locatelli, F., Gascon, P. (2009). Is Nephrology More at Ease Than Oncology with Erythropoiesis-Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks. The Oncologist 14: 57-62 [Abstract] [Full Text]  
• van der Meer, P, Groenveld, H F, Januzzi, J L Jr, van Veldhuisen, D J (2009). Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95: 1309-1314 [Abstract] [Full Text]  
• Smith, K., Semple, D., Bhandari, S., Seymour, A.-M. L. (2009). Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?. Eur J Heart Fail 11: 732-738 [Abstract] [Full Text]  
• McMurray, J. J.V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., Young, J. B., on behalf of the RED-HF Committees and Investigato, (2009). Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11: 795-801 [Abstract] [Full Text]  
• Mehdi, U., Toto, R. D. (2009). Anemia, Diabetes, and Chronic Kidney Disease. Diabetes Care 32: 1320-1326 [Full Text]  
• Macdougall, I. C. (2009). Anaemia ERBP Position statement. Nephrol Dial Transplant 24: 2288-2288 [Full Text]  
• Ishani, A., Guo, H., Arneson, T. J., Gilbertson, D. T., Mau, L.-W., Li, S., Dunning, S., Collins, A. J. (2009). Possible Effects of the New Medicare Reimbursement Policy on African Americans with ESRD. J. Am. Soc. Nephrol. 20: 1607-1613 [Full Text]  
• Singh, A. K., Himmelfarb, J., Szczech, L. A. (2009). Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro. J. Am. Soc. Nephrol. 20: 1436-1443 [Abstract] [Full Text]  
• Moossavi, S., Freedman, B. I. (2009). Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life. Arch Intern Med 169: 1100-1101 [Full Text]  
• Clement, F. M., Klarenbach, S., Tonelli, M., Johnson, J. A., Manns, B. J. (2009). The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Arch Intern Med 169: 1104-1112 [Abstract] [Full Text]  
• Nguyen, T. V. (2009). Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. Am J Health Syst Pharm 66: 1101-1104 [Abstract] [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Chan, K., Moran, J., Hlatky, M., Lafayette, R. (2009). Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 24: 1956-1962 [Abstract] [Full Text]  
• Anker, S. D., Voors, A., Okonko, D., Clark, A. L., James, M. K., von Haehling, S., Kjekshus, J., Ponikowski, P., Dickstein, K., for the OPTIMAAL Investigators, (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 30: 1331-1339 [Abstract] [Full Text]  
• Vanholder, R., Abramowicz, D., Cannata-Andia, J. B., Cocchi, V., Cochat, P., Covic, A., Eckardt, K.-U., Fouque, D., Heimburger, O., Jenkins, S., MacLeod, A., Lindley, E., Locatelli, F., London, G., Marti i Monros, A., Spasovski, G., Tattersall, J., Van Biesen, W., Wanner, C., Wiecek, A., Zoccali, C. (2009). The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2: 213-221 [Full Text]  
• Anderson, S., Halter, J. B., Hazzard, W. R., Himmelfarb, J., Horne, F. M., Kaysen, G. A., Kusek, J. W., Nayfield, S. G., Schmader, K., Tian, Y., Ashworth, J. R., Clayton, C. P., Parker, R. P., Tarver, E. D., Woolard, N. F., High, K. P., for the workshop participants, (2009). Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults. J. Am. Soc. Nephrol. 20: 1199-1209 [Abstract] [Full Text]  
• Tonelli, M., Hemmelgarn, B., Reiman, T., Manns, B., Reaume, M. N., Lloyd, A., Wiebe, N., Klarenbach, S. (2009). Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180: E62-E71 [Abstract] [Full Text]  
• Arneson, T. J., Zaun, D., Peng, Y., Solid, C. A., Dunning, S., Gilbertson, D. T. (2009). Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 24: 1378-1383 [Full Text]  
• Spiegel, D. M., Chertow, G. M. (2009). Lost Without Directions: Lessons from the Anemia Debate and the Drive Study. CJASN 4: 1009-1010 [Abstract] [Full Text]  
• Vaziri, N. D., Zhou, X. J. (2009). Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24: 1082-1088 [Full Text]  
• Parfrey, P. S., Lauve, M., Latremouille-Viau, D., Lefebvre, P. (2009). Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis. CJASN 4: 755-762 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2009). Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial. CJASN 4: 726-733 [Abstract] [Full Text]  
• Paragh, G., Kumar, S. M., Rakosy, Z., Choi, S.-C., Xu, X., Acs, G. (2009). RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A2780 Human Ovarian Carcinoma Cells. Am. J. Pathol. 174: 1504-1514 [Abstract] [Full Text]  
• Krikorian, S. A. (2009). Managing Anemia of Chronic Kidney Disease. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 3: 135-146 [Abstract]  
• Ibrahim, H. N., Foley, R. N., Zhang, R., Gilbertson, D. T., Collins, A. J. (2009). Parenteral Iron Use: Possible Contribution to Exceeding Target Hemoglobin in Hemodialysis Patients. CJASN 4: 623-629 [Abstract] [Full Text]  
• Bradbury, B. D., Danese, M. D., Gleeson, M., Critchlow, C. W. (2009). Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. CJASN 4: 630-637 [Abstract] [Full Text]  
• Minutolo, R., Chiodini, P., Cianciaruso, B., Pota, A., Bellizzi, V., Avino, D., Mascia, S., Laurino, S., Bertino, V., Conte, G., De Nicola, L. (2009). Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease. CJASN 4: 552-559 [Abstract] [Full Text]  
• Zhang, Y., Thamer, M., Cotter, D., Kaufman, J., Hernan, M. A. (2009). Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United States. CJASN 4: 638-644 [Abstract] [Full Text]  
• Kalantar-Zadeh, K., Aronoff, G. R. (2009). Hemoglobin Variability in Anemia of Chronic Kidney Disease. J. Am. Soc. Nephrol. 20: 479-487 [Abstract] [Full Text]  
• Kazory, A., Ross, E. A. (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53: 639-647 [Abstract] [Full Text]  
• Pagourelias, E. D., Koumaras, C., Kakafika, A. I., Tziomalos, K., Zorou, P. G., Athyros, V. G., Karagiannis, A. (2009). Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. ANGIOLOGY 60: 74-81 [Abstract]  
• Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., Pereira, B. J.G. (2009). Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. CJASN 4: 386-393 [Abstract] [Full Text]  
• Krapf, R., Hulter, H. N. (2009). Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). CJASN 4: 470-480 [Abstract] [Full Text]  
• Paige, N. M., Nagami, G. T. (2009). The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew. Mayo Clin Proc. 84: 180-186 [Abstract] [Full Text]  
• Heung, M., Mueller, B. A, Segal, J. H (2009). Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease. The Annals of Pharmacotherapy 43: 276-282 [Abstract] [Full Text]  
• Finkelstein, F. O., Story, K., Firanek, C., Mendelssohn, D., Barre, P., Takano, T., Soroka, S., Mujais, S. (2009). Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients. CJASN 4: 33-38 [Abstract] [Full Text]  
• Staples, A. O., Wong, C. S., Smith, J. M., Gipson, D. S., Filler, G., Warady, B. A., Martz, K., Greenbaum, L. A. (2009). Anemia and Risk of Hospitalization in Pediatric Chronic Kidney Disease. CJASN 4: 48-56 [Abstract] [Full Text]  
• de Francisco, A. L. M. (2009). Key insights into present and future treatments of anaemia in CKD patients. NDT Plus 2: i1-i2 [Full Text]  
• Anker, S. D., Toto, R. (2009). Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus 2: i3-i8 [Abstract] [Full Text]  
• de Francisco, A. L. M., Stenvinkel, P., Vaulont, S. (2009). Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2: i18-i26 [Abstract] [Full Text]  
• Metzger, N. L., Francis, K. E., Voils, S. A. (2008). A Comparative Review of Erythropoiesis Stimulating Agents. Journal of Pharmacy Practice 21: 424-430 [Abstract]  
• Saltiel, M. (2008). The Erythropoietic Receptors Agonists: FDA Warnings, Changing Guidelines, and Other Responses to Negative Data. Journal of Pharmacy Practice 21: 402-404 [Abstract]  
• Silverberg, D. S., Wexler, D., Iaina, A., Schwartz, D. (2008). The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure. Journal of Pharmacy Practice 21: 420-423 [Abstract]  
• Smith, L. E. H. (2008). Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture. IOVS 49: 5177-5182 [Full Text]  
• Radbill, B., Murphy, B., LeRoith, D. (2008). Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clin Proc. 83: 1373-1381 [Abstract] [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Akizawa, T., Pisoni, R. L., Akiba, T., Saito, A., Fukuhara, S., Asano, Y., Hasegawa, T., Port, F. K., Kurokawa, K. (2008). Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 23: 3643-3653 [Abstract] [Full Text]  
• Canaud, B., Mingardi, G., Braun, J., Aljama, P., Kerr, P. G., Locatelli, F., Villa, G., Van Vlem, B., McMahon, A. W., Kerloeguen, C., Beyer, U., on behalf of the STRIATA Study Investigators, (2008). Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23: 3654-3661 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2008). Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. CJASN 3: 1669-1675 [Abstract] [Full Text]  
• Summers, S., Holdsworth, S., Sharples, E. (2008). The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 23: 3053-3055 [Full Text]  
• Groenveld, H. F., Januzzi, J. L., Damman, K., van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J., van der Meer, P. (2008). Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis. J Am Coll Cardiol 52: 818-827 [Abstract] [Full Text]  
• Chonchol, M., Lippi, G., Montagnana, M., Muggeo, M., Targher, G. (2008). Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant 23: 2879-2883 [Abstract] [Full Text]  
• Chan, K. E., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., Moran, J. (2008). Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 23: 2948-2956 [Abstract] [Full Text]  
• Silverberg, D. S., Wexlerb, D., Iaina, A., Schwartz, D. (2008). The role of correction of anaemia in patients with congestive heart failure: A short review. Eur J Heart Fail 10: 819-823 [Abstract] [Full Text]  
• Courneya, K. S., Jones, L. W., Peddle, C. J., Sellar, C. M., Reiman, T., Joy, A. A., Chua, N., Tkachuk, L., Mackey, J. R. (2008). Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial. The Oncologist 13: 1012-1020 [Abstract] [Full Text]  
• Anand, I. S. (2008). Anemia and Chronic Heart Failure: Implications and Treatment Options. J Am Coll Cardiol 52: 501-511 [Abstract] [Full Text]  
• Zarychanski, R. MD, Houston, D. S. MD PhD (2008). Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?. CMAJ 179: 333-337 [Full Text]  
• Dong, X., de Leon, C. M., Artz, A., Tang, Y., Shah, R., Evans, D. (2008). A Population-Based Study of Hemoglobin, Race, and Mortality in Elderly Persons. J Gerontol A Biol Sci Med Sci 63: 873-878 [Abstract] [Full Text]  
• Schlieper, G., Hristov, M., Brandenburg, V., Kruger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N., Gladziwa, U., Ketteler, M., Weber, C., Floege, J. (2008). Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrol Dial Transplant 23: 2611-2618 [Abstract] [Full Text]  
• Swinkels, D. W., Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23: 2450-2453 [Full Text]  
• Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., Pereira, B. J. G. (2008). Ferumoxytol for Treating Iron Deficiency Anemia in CKD. J. Am. Soc. Nephrol. 19: 1599-1605 [Abstract] [Full Text]  
• Wolf, M. (2008). Active Vitamin D and Survival. J. Am. Soc. Nephrol. 19: 1442-1443 [Full Text]  
• Maekawa, K., Shoji, T., Emoto, M., Okuno, S., Yamakawa, T., Ishimura, E., Inaba, M., Nishizawa, Y. (2008). Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant 23: 2329-2336 [Abstract] [Full Text]  
• Chhabra, D., Grafals, M., Skaro, A. I., Parker, M., Gallon, L. (2008). Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection. CJASN 3: 1168-1174 [Abstract] [Full Text]  
• Brookhart, M. A., Schneeweiss, S., Avorn, J., Bradbury, B. D., Rothman, K. J., Fischer, M., Mehta, J., Winkelmayer, W. C. (2008). The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. J. Am. Soc. Nephrol. 19: 1389-1395 [Abstract] [Full Text]